Chart Events
Performance Outlook
| Previous Close | 1.1700 |
| Open | 1.1700 |
| Bid | 1.1200 x 1400 |
| Ask | 1.1300 x 1300 |
| Day's Range | 1.1000 - 1.1700 |
| 52 Week Range | 1.1000 - 3.3072 |
| Volume | |
| Avg. Volume | 4,125,076 |
| Market Cap | 430.814M |
| Beta (5Y Monthly) | 1.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8500 |
| Earnings Date | Nov 06, 2023 - Nov 10, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AGEN
Related Research
- Agenus Inc.Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.RatingFair ValueEconomic Moat17 hours agoMorningstar
Business WireAgenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass., September 01, 2023--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted, as of September 1, 2023 ("Grant Date"), inducement awards to Robin Taylor, Ph.D. in connection with his appointment as Chief Commercial Officer. The Compensation Committee approved the awards pursuant to Agenus' 2015 Inducement Equity Plan and in accordance wi
Motley Fool3 Magnificent Growth Stocks to Buy on the Dip
Growth stocks have lost momentum in August after a strong start to the year. Innovative companies in the fields of drug development and medical imaging, such as Agenus (NASDAQ: AGEN), BioCryst Pharmaceuticals (NASDAQ: BCRX), and Nano-X Imaging (NASDAQ: NNOX) have all experienced a significant drop in their stock prices in the past 30 days.
Business WireAgenus to Participate in September Investor Conferences
LEXINGTON, Mass.LEXINGTON, Mass., August 28, 2023--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in the following upcoming investor conferences:
